Transgene's novel Liver Cancer drug shows promise in latest animal studies.

February 10, 2010

Transgene Biotek announced today that a novel drug for Liver Cancer developed by its scientists has demonstrated excellent efficacy in the latest animal studies. This corroborates earlier data gathered from in-vitro studies.

Transgene has employed its RNAi platform, which utilizes a novel gene silencing technology, to develop this drug. This technology involves highly selective knock-down of specific liver cancer producing gene targets, which has demonstrated remarkable regression of the tumours in tests. The other important piece of the technology comes from Transgene's ability to generate its own novel mutant vectors for highly efficient drug delivery, which is vital in the treatment of such cancers.

Liver cancer is the fifth most common cancer in the world, and the third most common cause of cancer mortality. A deadly cancer, liver cancer kills almost all patients who have it within a year, and only 5% of patients with liver cancer that has begun to cause symptoms survive even five years without treatment. Unlike Transgene's new Hepatic cancer drug, traditional drugs used in cancer chemotherapy are non-selective, and induce DNA damage leading to tumor relapse.

Since outlicensing its Orlistat technology to a major pharma company, Transgene has been moving full steam ahead with several products from its product pipeline based on its unique technology platforms, and the company expects to achieve more milestones in the near future.